20 May 2023 |
Tessera Therapeutics Presents New Data Demonstrating the Potential of Gene Writing™ Technology at the American Society of Gene and Cell Therapy 26th Annual Meeting
|
20 May 2023 |
Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting
|
20 May 2023 |
RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in Glioblastoma Multiforme Patients
|
20 May 2023 |
KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
|
20 May 2023 |
Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial
|
20 May 2023 |
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
|
20 May 2023 |
Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting
|
20 May 2023 |
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
|
20 May 2023 |
2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
|
19 May 2023 |
Orna Therapeutics Unveils Progress of Circular RNA Platform and Improvements in Lead Program ORN-101 at PEGS and ASGCT
|
19 May 2023 |
CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.
|
19 May 2023 |
Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
|
19 May 2023 |
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting
|
19 May 2023 |
Rejuvenate Bio Announces Data for Gene Therapy RJB-01 in Mitral Valve Disease at 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)
|
18 May 2023 |
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
|
18 May 2023 |
Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy™ for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy
|
18 May 2023 |
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
|
18 May 2023 |
IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
|
18 May 2023 |
Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity
|
18 May 2023 |
CANbridge and UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy (CAN203) Improves Lifespan and Motor Function in Mice When Administered via Intracerebroventricular Injection
|
18 May 2023 |
Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer
|
17 May 2023 |
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
|
17 May 2023 |
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
|
17 May 2023 |
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting
|
17 May 2023 |
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
|